Biphenotypic acute leukaemia: A case series

Ahmed Aribi; Carlos Bueso-Ramos; Eli Estey; Zeev Estrov; Susan O'Brien; Francis Giles; Stefan Faderl; Deborah Thomas; Partow Kebriaei; Guillermo Garcia-Manero; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi

doi:10.1111/j.1365-2141.2007.06634.x

Biphenotypic acute leukaemia: A case series

Ahmed Aribi
, Carlos Bueso-Ramos
, Eli Estey
, Zeev Estrov
, Susan O'Brien
, Francis Giles
, Stefan Faderl
, Deborah Thomas
, Partow Kebriaei
, Guillermo Garcia-Manero
, Sherry Pierce
, Jorge Cortes
, Hagop Kantarjian
, Farhad Ravandi

The University of Texas Health Science Center at Houston

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

48 Citations (Scopus)

Abstract

Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

Original language	English
Pages (from-to)	213-216
Number of pages	4
Journal	British Journal of Haematology
Volume	138
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2141.2007.06634.x
Publication status	Published - Jul 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Biphenotypic acute leukaemia
Diagnosis
Immnuophenotype
Prognosis
Therapy

Access to Document

10.1111/j.1365-2141.2007.06634.x

Cite this

@article{d74e00b24ca74a69b1dd5a2fd24fcd1c,

title = "Biphenotypic acute leukaemia: A case series",

abstract = "Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78\% and 57\% were noted respectively. The overall survival probability at 2 years was 60\%.",

keywords = "Biphenotypic acute leukaemia, Diagnosis, Immnuophenotype, Prognosis, Therapy",

author = "Ahmed Aribi and Carlos Bueso-Ramos and Eli Estey and Zeev Estrov and Susan O'Brien and Francis Giles and Stefan Faderl and Deborah Thomas and Partow Kebriaei and Guillermo Garcia-Manero and Sherry Pierce and Jorge Cortes and Hagop Kantarjian and Farhad Ravandi",

year = "2007",

month = jul,

doi = "10.1111/j.1365-2141.2007.06634.x",

language = "English",

volume = "138",

pages = "213--216",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc",

number = "2",

}

TY - JOUR

T1 - Biphenotypic acute leukaemia

T2 - A case series

AU - Aribi, Ahmed

AU - Bueso-Ramos, Carlos

AU - Estey, Eli

AU - Estrov, Zeev

AU - O'Brien, Susan

AU - Giles, Francis

AU - Faderl, Stefan

AU - Thomas, Deborah

AU - Kebriaei, Partow

AU - Garcia-Manero, Guillermo

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

PY - 2007/7

Y1 - 2007/7

N2 - Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

AB - Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

KW - Biphenotypic acute leukaemia

KW - Diagnosis

KW - Immnuophenotype

KW - Prognosis

KW - Therapy

UR - https://www.scopus.com/pages/publications/34250804050

U2 - 10.1111/j.1365-2141.2007.06634.x

DO - 10.1111/j.1365-2141.2007.06634.x

M3 - Article

C2 - 17593028

AN - SCOPUS:34250804050

SN - 0007-1048

VL - 138

SP - 213

EP - 216

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Biphenotypic acute leukaemia: A case series

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this